U.S. flag

An official website of the United States government

PMC Full-Text Search Results

Items: 2

1.
Figure 2

Figure 2. From: Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group.

This graph illustrates the estimated GFR versus time (in months) prior to and after completion of the 6-month FONT Treatment Period in patients assigned to adalimumab.

Alexandra Peyser, et al. BMC Nephrol. 2010;11:2-2.
2.
Figure 1

Figure 1. From: Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group.

This graph illustrates the estimated GFR versus time (in months) prior to and after completion of the 6-month FONT Treatment Period in patients assigned to rosiglitazone.

Alexandra Peyser, et al. BMC Nephrol. 2010;11:2-2.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Support Center